Thirdly, being a PPAR-γ agonist, it displays a direct antiviral activity, and finally, PPAR-γ agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients [24]. The gene discussed is PPARG; the disease is pulmonary fibrosis.